Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib

Proteomic Profiling of BRAFV600E Mutant Colon Cancer Cells Reveals the Involvement of Nucleophosmin/c-Myc Axis in Modulating the Response and Resistance to BRAF Inhibition by Vemurafenib

BRAFV600E mutations are found in approximately 10% of colorectal cancer patients and are associated with worse prognosis and poor outcomes with systemic therapies. The aim of this study was to identify novel druggable features of BRAFV600E-mutated colon cancer (CC) cells associated with the response...

Full description

Bibliographic Details
Main Authors: Petra Grbčić, Dora Fučkar Čupić, Tania Gamberi, Sandra Kraljević Pavelić, Mirela Sedić
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:International Journal of Molecular Sciences
Subjects:
colorectal cancer
BRAFV600E mutation
vemurafenib
PLX4032
chemoresistance
nucleophosmin
Online Access:https://www.mdpi.com/1422-0067/22/12/6174

Internet

https://www.mdpi.com/1422-0067/22/12/6174

Similar Items